This is a preview of subscription content, log in via an institution to check access.
Notes
2017 US dollars
Advisory Committee on Immunization Practices
Reference
Stoecker C, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine : 27 Dec 2019. Available from: URL: http://doi.org/10.1016/j.vaccine.2019.12.029
Rights and permissions
About this article
Cite this article
PCV13 vaccination at age 65 not cost effective with childhood PCV13. PharmacoEcon Outcomes News 845, 23 (2020). https://doi.org/10.1007/s40274-020-6526-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6526-x